Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Upgraded at BidaskClub
BidaskClub upgraded shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning.
A number of other equities analysts also recently weighed in on ALXN. Royal Bank Of Canada reissued an outperform rating and set a $177.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, March 27th. UBS AG initiated coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 29th. They issued a buy rating and a $138.00 price target for the company. Instinet reaffirmed a buy rating and issued a $148.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, March 30th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, April 18th. Finally, Cowen and Company reaffirmed an outperform rating and issued a $180.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, April 28th. Six analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $156.85.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up 3.04% during trading on Tuesday, reaching $137.99. 2,475,082 shares of the company were exchanged. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $145.41. The stock’s 50-day moving average is $123.43 and its 200-day moving average is $122.81. The firm has a market cap of $30.91 billion, a price-to-earnings ratio of 59.84 and a beta of 1.39.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter last year, the firm earned $1.13 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals will post $5.41 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-nasdaqalxn-upgraded-at-bidaskclub/1461296.html.
In other news, CEO Ludwig Hantson purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the acquisition, the chief executive officer now owns 38,725 shares in the company, valued at $4,519,982. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 660,779 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were purchased at an average price of $117.33 per share, for a total transaction of $77,529,200.07. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 2,019,734 shares of company stock worth $235,606,846. 4.35% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. IPG Investment Advisors LLC bought a new position in Alexion Pharmaceuticals during the second quarter worth $208,000. Daiwa Securities Group Inc. boosted its position in Alexion Pharmaceuticals by 3.3% in the second quarter. Daiwa Securities Group Inc. now owns 6,300 shares of the biopharmaceutical company’s stock worth $767,000 after buying an additional 200 shares during the last quarter. Edge Wealth Management LLC bought a new position in Alexion Pharmaceuticals during the second quarter worth $1,581,000. Grove Bank & Trust boosted its position in Alexion Pharmaceuticals by 194.7% in the second quarter. Grove Bank & Trust now owns 1,347 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 890 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock worth $87,772,000 after buying an additional 721,367 shares during the last quarter. Hedge funds and other institutional investors own 94.84% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.